featured
Perioperative Chemotherapy With or Without Bevacizumab in Operable Esophagogastric Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Peri-Operative Chemotherapy With or Without Bevacizumab in Operable Oesophagogastric Adenocarcinoma (UK Medical Research Council ST03): Primary Analysis Results of a Multicentre, Open-Label, Randomised Phase 2-3 Trial
Lancet Oncol 2017 Feb 02;[EPub Ahead of Print], D Cunningham, SP Stenning, EC Smyth, AF Okines, WH Allum, S Rowley, L Stevenson, HI Grabsch, D Alderson, T Crosby, SM Griffin, W Mansoor, FY Coxon, SJ Falk, S Darby, KA Sumpter, JM Blazeby, RE LangleyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.